Few research peptides have attracted as much attention in Canada over the past two years as Retatrutide. Search interest has climbed steadily since the first phase 2 results were published, and Canadian researchers, biohackers and supplier-comparison shoppers now ask a remarkably consistent set of questions: what the compound is, how it differs from Semaglutide and Tirzepatide, whether it is legal to order, how it should be stored, and what to look for on a certificate of analysis.
Much of the information circulating online is either recycled from US-centric sources that do not account for Canadian regulations and shipping realities, or comes from forums where enthusiasm outruns accuracy. This article collects the thirteen questions Canadian readers ask most often and answers each one directly, with clinical-trial findings described cautiously and regulatory status stated plainly.
One point applies throughout: Retatrutide is an investigational compound sold for laboratory research. It has not been approved by Health Canada or the FDA for human use, and nothing here is medical advice. The answers below are written for people who want to understand the compound and the market around it, not for anyone seeking a treatment protocol.
1. What exactly is Retatrutide?
Retatrutide is a synthetic peptide developed by Eli Lilly that acts as an agonist at three receptors simultaneously: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor. This triple-agonist design is what distinguishes it from the earlier generation of incretin-based compounds. Semaglutide targets GLP-1 alone; Tirzepatide targets GLP-1 and GIP; Retatrutide adds glucagon receptor activity to the combination.
Structurally it is a single peptide chain modified with a fatty-acid side chain that extends its half-life, allowing once-weekly administration in the clinical trials. The development code was LY3437943, and readers will still find that designation in older literature and on some supplier listings.
2. What have the clinical trials shown so far?
The most widely cited data come from a phase 2 trial published in 2023, which enrolled adults with obesity or overweight and followed them for roughly 48 weeks. The trial reported substantial dose-dependent mean weight reduction, with the higher doses producing average losses that exceeded what had been reported for earlier single- and dual-agonist compounds over comparable periods. A companion phase 2 study in people with type 2 diabetes reported improvements in glycaemic markers alongside weight reduction.
The most frequently reported adverse effects were gastrointestinal, consistent with the incretin class as a whole, and the investigators noted that these tended to occur during dose escalation. The phase 3 programme, called TRIUMPH, is ongoing and is examining the compound across several populations including obesity with and without related conditions. Until phase 3 results are published and reviewed, the phase 2 findings should be treated as promising but preliminary. Researchers should read the primary publications rather than summaries when precision matters.
3. Is Retatrutide legal to buy in Canada?
Retatrutide is not an approved drug in Canada, so it cannot be prescribed, dispensed or marketed for human use. It is available as a research chemical, and Canadian suppliers sell it for laboratory use only, with that restriction stated on the product listing. Buying a research peptide for research purposes is not the same as buying a medication, and suppliers who are clear about this distinction are the ones operating responsibly.
Canadian readers comparing sources will notice that domestic listings for Retatrutide canada researchers can order from a supplier such as NOX Peptides Canada carry explicit research-use labelling, while some overseas marketplaces are vaguer. Clarity on this point is a useful marker of a supplier that understands its regulatory obligations. Anyone considering the compound for any purpose other than research should speak to a licensed physician, because there is no lawful route to human use in Canada at present.
4. How is Retatrutide different from Tirzepatide and Semaglutide?
The three compounds are often grouped together, but the receptor profile differs in each case and that difference is the core of the research interest:
- Semaglutide is a GLP-1 receptor agonist. It is approved in Canada for type 2 diabetes and for chronic weight management under different brand names.
- Tirzepatide is a dual GLP-1 and GIP receptor agonist, also approved in Canada for type 2 diabetes and, more recently, for weight management.
- Retatrutide adds glucagon receptor agonism to the GLP-1 and GIP activity and remains investigational.
The hypothesis behind adding glucagon activity is that it may increase energy expenditure and hepatic fat metabolism, complementing the appetite-related effects of GLP-1 and GIP. Whether that translates into a durable advantage over Tirzepatide in head-to-head phase 3 comparisons is one of the open questions the TRIUMPH programme is designed to address.
5. What vial sizes are available and what do the numbers mean?
Research-grade Retatrutide is sold as a lyophilised (freeze-dried) powder in glass vials. Common sizes include 5 mg, 10 mg, 20 mg and 30 mg. The number refers to the nominal quantity of peptide in the vial before reconstitution. Larger vials such as the 30 mg format stocked by NOX Peptides Canada have become popular because they lower the per-milligram cost and reduce the number of shipments a research programme requires.
Two caveats apply to the label figure. The powder may include residual water and counter-ions, so net peptide content can be slightly lower than the gross weight; and the figure is only as reliable as the testing behind it. A certificate of analysis with a quantitative assay is the way to confirm the label.
6. How should Retatrutide be stored?
As a lyophilised powder, Retatrutide is relatively stable when kept cold, dark and dry. Suppliers generally recommend refrigeration at roughly 2 to 8 degrees Celsius for short-term storage and freezer storage for longer periods, with the vial kept sealed and protected from light. Once reconstituted with bacteriostatic water, the solution is considerably less stable and should be refrigerated and used within the period the supplier specifies, avoiding repeated freeze-thaw cycles.
Temperature excursions during shipping are the most common cause of degradation before the vial ever reaches a lab, which is one reason domestic shipping is preferred by many Canadian researchers. A vial that spends a fortnight crossing borders in summer has a different history from one that travels two days within the country. Labelling each vial with the date of receipt and the date of reconstitution is a simple habit that keeps a lab’s inventory honest and makes it obvious when material has been sitting too long to trust.
7. What does reconstitution involve, in lab terms?
Reconstitution means dissolving the lyophilised powder in a sterile diluent, typically bacteriostatic water, to produce a solution of known concentration. The arithmetic is simple: the peptide mass divided by the diluent volume gives the concentration. A 30 mg vial reconstituted with 3 mL yields a nominal 10 mg per mL; the same vial with 6 mL yields 5 mg per mL. Insulin-style syringes are marked in units, where 100 units equals 1 mL, so 10 units corresponds to 0.1 mL of whatever concentration is in the vial.
This is laboratory arithmetic used to prepare solutions for in-vitro or analytical work. It is not an instruction for self-administration, and the compound is not approved for human use. Online peptide calculators simply automate this calculation and are useful for avoiding decimal-point errors.
8. What should a certificate of analysis for Retatrutide include?
A meaningful COA is batch-specific and comes from an independent laboratory rather than the supplier itself. At minimum it should show:
- The compound name and the batch or lot number matching the vial label
- A purity figure determined by high-performance liquid chromatography (HPLC)
- Identity confirmation by mass spectrometry showing the expected molecular weight
- The testing laboratory’s name and the date of analysis
- Ideally, a quantitative assay or net peptide content figure
Suppliers who publish these documents openly are giving researchers the means to verify what they are buying. NOX Peptides Canada publishes third-party COAs for its Retatrutide batches, and comparing the lot number on the certificate with the one on the vial is a two-second check that many buyers skip. A certificate with no lot number, or one that is several years old, is not evidence of the current batch’s quality.
9. Why do Canadian prices for Retatrutide vary so widely?
Pricing reflects vial size, purity, whether third-party testing is included, the currency of the listing, shipping and handling costs, and supplier overhead. Demand also plays a role: Retatrutide is among the most sought-after research peptides, and some vendors price accordingly. The fairest comparison converts each listing to a landed Canadian-dollar cost per milligram with documentation attached. On that basis, a domestic listing that appears more expensive per vial frequently turns out to be cheaper per usable milligram than an overseas alternative once duties, brokerage fees and exchange rates are included.
10. What happens at the border when Retatrutide is imported?
Parcels entering Canada are subject to inspection by the Canada Border Services Agency, and research chemicals can be held for examination, particularly if the declaration is unclear or the paperwork is incomplete. Duties, GST or HST, and courier brokerage fees may be assessed on delivery. Delays of days or weeks are not unusual, and during that time the parcel is not temperature-controlled. There is also the possibility of refusal or seizure if a shipment is judged to be intended for human use rather than research.
Ordering from a Canadian supplier avoids the border entirely. The parcel moves within the domestic postal or courier network, there are no import formalities, and the supplier is subject to Canadian consumer protection rules if something goes wrong.
11. How can a buyer tell whether a Retatrutide vial is authentic?
No visual inspection can confirm identity or purity; a white lyophilised powder looks the same whether it is Retatrutide, a different peptide, or something inert. Authenticity rests on documentation and supplier accountability. Practical checks include matching the lot number on the vial to a published COA, confirming that the COA’s mass spectrometry result shows the expected molecular weight for Retatrutide, and buying from a supplier with a verifiable Canadian business presence. Researchers with access to analytical equipment can run their own HPLC or mass spectrometry, and some independent laboratories accept samples for testing. A supplier who welcomes that scrutiny is behaving as a reagent vendor should.
12. What are the known safety signals from the trials?
The phase 2 trials reported that the most common adverse events were gastrointestinal, including nausea, diarrhoea, vomiting and constipation, and that these were generally mild to moderate and more frequent during dose escalation. Increases in heart rate were observed, as has been reported with other incretin-based compounds. Longer-term safety, effects in broader populations, and rare events can only be characterised in the larger phase 3 programme. These are trial findings in supervised clinical settings and cannot be extrapolated to any other context. The compound is not approved for human use, and this article does not offer guidance on its use.
13. Where should Canadian researchers buy Retatrutide?
The criteria that matter are the same for any research reagent: batch-specific third-party testing, transparent research-use labelling, domestic shipping with attention to temperature, clear policies on damaged or lost shipments, and a business that can be contacted. Supplier types on the market include large US research-peptide warehouses, overseas marketplaces of variable reliability, and a smaller number of Canadian suppliers. Among the domestic options, NOX Peptides Canada stocks Retatrutide in a 30 mg vial with published COAs and ships within Canada, which addresses the border, currency and cold-chain questions raised earlier in this article at the same time.
Final Thoughts
Retatrutide has earned its place as one of the most discussed research peptides in Canada, and the questions above reflect a readership that wants accurate information rather than hype. The compound’s triple-agonist mechanism is scientifically interesting, the phase 2 results were notable, and the phase 3 TRIUMPH programme will determine whether the early promise holds up. Until then, it remains an investigational reagent for laboratory study.
For researchers who have decided the compound belongs in their programme, the practical decisions come down to sourcing. Verifying a certificate of analysis, keeping the purchase domestic, and understanding storage requirements will prevent most of the problems that buyers report. A Canadian supplier such as NOX Peptides Canada makes those checks easier by publishing testing and shipping from within the country, and that combination is the standard against which any other source should be measured.
